SRRK Stock Analysis: Buy, Sell, or Hold?
SRRK - Scholar Rock Holding Corporation Common Stock
$43.02
0.42 (0.99%)
▲
5d:
-1.47%
30d:
-2.82%
90d:
-5.8%
BUY
MODERATE Confidence
Analysis Updated: Mar 30, 2026 12:00 AM ET
Earnings: May 13, 2026
Smart Money Distribution
SRRK is up 3.9% this week, but smart money is buying puts. Top strike: $35 2026-05-15 with 1 OI. Put ratio: 100% View Scanner →
Strength: 7.0/10
Get Alerted When SRRK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: SRRK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: SRRK shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: SRRK is currently trading at $43.02, which is considered fair relative to its 30-day fair value range of $42.16 to $46.87.
Technical Outlook: Technically, SRRK is in a uptrend. Immediate support is located at $38.75, while resistance sits at $47.87.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $56.07 (+31.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, SRRK is in a uptrend. Immediate support is located at $38.75, while resistance sits at $47.87.
Market Sentiment: The stock shows a mixed technical setup (45/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $56.07 (+31.6%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$42.16 -
$46.87
Company Quality Score
54/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.7%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (45/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 31.6% below Wall St target ($56.07)
Fair Price Analysis
30-Day Fair Range
$42.16 -
$46.87
Current vs Fair Value
FAIR
Support & Resistance Levels
Support Level
$38.75
Resistance Level
$47.87
Current Trend
Uptrend
Technical data as of
Mar 30, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-18.39
Wall Street Target
$56.07
(+31.6%)
Revenue Growth (YoY)
-100.0%
Share & Embed Analysis
Last updated: March 30, 2026 3:18 PM ET
Data refreshes hourly during market hours. Next update: 4:18 PM
Data refreshes hourly during market hours. Next update: 4:18 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is SRRK showing a specific setup today?
Insider Activity (6 Months)
3
Buys
17
Sells
Net
INSIDERS SELLING
Recent Transactions
Mo Qatanani
SELL
8484 shares
2026-02-23
Caryn Parlavecchio
SELL
9035 shares
2026-02-17
Mo Qatanani
SELL
7989 shares
2026-02-17
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$222 | 59 HOLD |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$92 | 62 BUY |
|
RARE
Ultragenyx |
STRONG BUY
20 analysts |
$54 | 53 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$108 | 61 BUY |
|
MDGL
Madrigal Pharmaceuticals… |
STRONG BUY
15 analysts |
$669 | 67 BUY |
Advanced SRRK Option Strategies
Professional options setups generated by AI based on today's SRRK price and gamma walls.
